Virbac Logo

Virbac

Develops animal health pharma, vaccines & diagnostics for vets, farmers & pet owners globally.

FR000 | PA

Overview

Corporate Details

ISIN(s):
FR0000031577
LEI:
969500QQ1X5XHG649644
Country:
France
Address:
1ERE AVENUE, 06510 CARROS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Virbac is an independent pharmaceutical company exclusively dedicated to animal health. Founded in 1968 by a veterinarian, the company develops, manufactures, and distributes a comprehensive range of products and services for veterinarians, farmers, and pet owners. Operating in over 100 countries, its portfolio offers innovative solutions covering the majority of animal species and diseases. Key product areas include pharmaceuticals, vaccines, parasite control, dental care, nutritional supplements, and diagnostic tools, all aimed at shaping the future of animal health.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 17:45
Earnings Release
VIRBAC: résultats semestriels 2025
French 1.2 MB
2025-09-12 17:45
Earnings Release
Virbac: 2025 Half-year results
English 1.1 MB
2025-09-12 17:30
Interim Report
Virbac : Rapport financier semestriel 2025
French 13.2 MB
2025-09-12 17:30
Interim Report
Virbac : Half-yearly financial report 2025
English 13.4 MB
2025-09-12 17:30
Report Publication Announcement
Virbac : Communiqué de mise à disposition du rapport financier semestriel au 30…
French 264.9 KB
2025-09-12 17:30
Report Publication Announcement
Virbac : Public release of the Half-Year Financial Report at 30 June 2025.
English 264.6 KB
2025-08-18 09:30
Remuneration Information
VIRBAC: Informations sur les conditions de rémunération de Paul Martingell
French 80.5 KB
2025-08-18 09:30
Remuneration Information
Virbac:: Paul Martingell's compensation terms
English 128.7 KB
2025-06-19 08:30
Board/Management Information
VIRBAC: Paul Martingell nommé directeur général du groupe Virbac au 1er septemb…
French 271.7 KB
2025-06-19 08:30
Board/Management Information
VIRBAC: Paul Martingell is appointed chief executive officer of Virbac, effecti…
English 279.3 KB
2025-06-10 09:59
Declaration of Voting Results & Voting Rights Announcements
Virbac : Declaration of the number of share and voting rights 05/2025
English 59.2 KB
2025-06-10 09:59
Declaration of Voting Results & Voting Rights Announcements
Virbac : Déclaration d'actions et de droits de vote 05/2025
French 36.6 KB
2025-05-26 10:05
Pre-Annual General Meeting Information
VIRBAC: Communiqué précisant les modalités de mise à disposition ou de consulta…
French 26.3 KB
2025-05-07 16:27
Declaration of Voting Results & Voting Rights Announcements
Virbac : Déclaration d'actions et de droits de vote 04/2025
French 36.6 KB
2025-04-28 19:00
Annual Report (ESEF)
Virbac : Rapport Annuel Virbac au 31 décembre 2024 (ESEF)
French 22.1 MB

Automate Your Workflow. Get a real-time feed of all Virbac filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Virbac via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-17 N/A Other Sell 370 135,790.00 EUR
2023-07-19 N/A Other Buy 950 245,100.00 EUR

Peer Companies

Company Country Ticker View
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France ALONC
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway OCIN
Oncolys BioPharma Inc. Logo
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
Japan 4588
Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland SKT
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan 4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel OPK
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea 131030
Oramed Pharmaceuticals Inc. Logo
Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.
Israel ORMP

Talk to a Data Expert

Have a question? We'll get back to you promptly.